Novartis AG v Agvantage Pty Ltd

The Federal Court of Australia was called upon to determine the issue of costs in a dispute between Novartis AG and Agvantage Pty Ltd. The dispute originated from a matter concerning the potential infringement of a patent by Agvantage Pty Ltd, specifically regarding the formulation of a product known as Dicyclanil. The parties had reached consent orders, but the issue of costs remained unresolved. The court was tasked with deciding how the costs associated with the originating application filed by the parties should be allocated.

In determining the appropriate allocation of costs, the court considered the nature of the dispute and the terms of the consent orders. The court found that the parties had agreed to bear their own costs in relation to the originating application, and as such, neither party was entitled to recover costs from the other. The court also dismissed the originating application on other grounds, finding that the application did not meet the necessary criteria for preliminary discovery.

The court's decision was based on the terms of the consent orders and the principles of cost allocation in litigation. The court held that since the parties had agreed to bear their own costs, there was no basis for one party to recover costs from the other. The court also found that the application for preliminary discovery did not meet the necessary criteria, and as such, the application was dismissed.

The final orders of the court provided that each party was to bear its own costs in relation to the originating application filed on 27 January 2012, and that the originating application was to be dismissed. The court's decision provided clarity on the issue of costs in the dispute between the parties, and resolved the remaining issue in the litigation.